CG
CLBT icon

Cutler Group’s Cellebrite CLBT Stock Holding History

Cutler Group’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-500
Closed -$1K – 5037
2022
Q1 		$1K Sell
500
-4,900
-91% -$32.5K ﹤0.01% 4913
2021
Q4 		$12K Sell
5,400
-27,600
-84% -$260K ﹤0.01% 3524
2021
Q3 		$54K Buy
+33,000
New +$345K ﹤0.01% 2445

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LSCM
Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.02B AUM 9.21% 1-Year Est. Return
IP
Isomer Partners New York $74.3M AUM 23.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MCM
Makena Capital Management Menlo Park, California $866M AUM 17.79% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Cutler Group's CLBT Position: Q4 2022 in Review

Cutler Group sold out of Cellebrite (CLBT) in Q4 2022, closing a stake of 368 shares — an estimated $1K sold.

Cutler Group first reported a position in CLBT in Q3 2021 and held it in 5 quarters. The position peaked at $66K in Q3 2021. 52 funds tracked by Wall St. Rank hold CLBT as of Q4 2022.

  • Cutler Group reported no remaining Cellebrite position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 368 Cellebrite shares in Q4 2022, an estimated $1K.
  • Cutler Group first reported a position in Cellebrite in Q3 2021 and held it in 5 quarters.
  • Cutler Group's Cellebrite position peaked at $66K in Q3 2021.
  • 52 funds tracked by Wall St. Rank held Cellebrite as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.